Patients with SM experience higher frequencies of multisystem symptoms both in the year before and after diagnosis.
Conventional tryptase thresholds (~11 μg/L) should be maintained rather than raised, and tryptase alone is insufficient to rule out SM.
Peg-interferon-alfa2a (peg-IFN-α) offers a promising approach for treating bone disease in non-advanced systemic mastocytosis.
A new study provides a detailed snapshot of organ damage in patients with advanced SM at the time of enrollment in clinical trials.
A recent case report describes the rare reoccurrence of mastocytosis in an adult patient 40 years after a childhood diagnosis.
A young girl with severe systemic mastocytosis (SM) experienced recurrent fainting episodes, initially misdiagnosed as reflex syncope.
An unusual case of anaphylaxis following ackee fruit ingestion led to the unexpected diagnosis of indolent systemic mastocytosis (SM).
High-throughput proteomics and machine learning helped uncover new protein signatures with useful prognostic implications in SM.
Avapritinib, a selective KIT D816V inhibitor, appears to produce long-term improvements in skin symptoms in patients with advanced SM.
A case of systemic mastocytosis in which recurrent vertebral fractures were the primary symptom was recently reported.
